IP Library Granted Patent US 11,684,797
Granted Patent B2
US 11,684,797 · App. 17/735,034 · Granted Jun 27, 2023

Laser assisted wound healing protocol and system

Inventor: Margaret Kalmeta (Irvine, CA)
Assignee: THE BIOREGENTECH INSTITUTE, INC.
A61N5/0603A61C1/0046A61K8/20A61K8/24A61K8/368A61K8/416A61K8/44A61K8/442A61K8/65A61K31/07A61K31/122A61K31/198A61K31/592A61K31/7004A61K31/714A61K33/00A61K33/14A61K33/24A61K33/242A61K33/243A61K33/26A61K33/34A61K33/38A61K33/42A61K38/39A61N1/40A61N5/062A61N5/0613A61N5/0624A61Q11/00A61Q19/00A61K2800/81A61N5/067A61N2005/063A61N2005/0606A61N2005/0651A61N2005/0659A61N2005/0663
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,684,797
App. No.
17/735,034
Granted
Jun 27, 2023
Kind
B2
Abstract

A method of treating diseased tissue while healing the wound using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 1.2 watts, used with intermittent stops to control tissue temperature and biostimulate epithelial regeneration when used with or without substrates. A method of treating diseased tissue using a laser light in the green wavelength range (520-570 nm) at a laser power of 0.001 W to 5 W. A method of treating diseased tissue using a laser light in the IR wavelength range (700-1400 nm) at a laser power of 0.001 W to 5 W.

Claims (32)

1. An aqueous or gel substrate for treating damage to a tissue in a form of an acute or chronic wound, comprising:

(1) collagen,

(2) 200 mg-6 g of hyaluronic acid,

(3) water,

(4) 0.1 g -1 g of Cu,

(5) 0.1 g -1 g of Fe, and

(6) 0.1 g -1 g of silver.

2. The substrate of claim 1 , wherein the collagen comprises collagen limed, collagen unlimed, or collagen supplemented with porous tricalcium phosphate crystals.

3. The substrate of claim 1 , wherein the silver is soluble.

4. The substrate of claim 1 , further comprising HCl.

5. The substrate of claim 1 , further comprising a phosphate comprising ATP.

6. The substrate of claim 1 , further comprising non-native or xenograft hyaluronic acid, and non-native or xenograft collagen limed or unlimed, the non-native or xenograft hyaluronic acid and non-native or xenograft collagen limed or unlimed not being found at or near the wound or any other damaged tissue.

7. The substrate of claim 1 , wherein the acute or chronic wound is located on an epithelial surface of the tissue.

8. The substrate of claim 1 , wherein the substrate further comprises an effective amount of tricalcium phosphate or dense or porous hydroxyapatite in a variety of crystal sizes.

9. The substrate of claim 1 , wherein the substrate comprises silver nanoparticles.

10. A method for treating damage to a tissue in a form of an acute or chronic wound, comprising:

placing an aqueous or gel substrate into the wound, the substrate comprising:

(1) collagen,

(2) 200 mg-6 g of hyaluronic acid,

(3) water,

(4) 0.1 g -1 g of Cu,

(5) 0.1 g -1 g of Fe, and

(6) 0.1 g -1 g of silver; and

causing tissue regeneration in the wound with the substrate, wherein the tissue regeneration facilitates healing of the wound.

11. The method of claim 10 , further comprising maintaining the substrate in the wound for a period of time, wherein a combination of the (1) collagen, (2) hyaluronic acid, (3) water, (4) Cu, (5) Fe, and (6) silver, is configured to cause the tissue regeneration in the wound and facilitate the healing of the wound.

12. The method of claim 10 , wherein the collagen comprises collagen limed, collagen unlimed, or collagen supplemented with porous tricalcium phosphate crystals.

13. The method of claim 10 , wherein the silver is soluble.

14. The method of claim 10 , the substrate further comprising HCl.

15. The method of claim 10 , the substrate further comprising a phosphate comprising ATP.

16. The method of claim 10 , the substrate further comprising non-native or xenograft hyaluronic acid, and non-native or xenograft collagen limed or unlimed, the non-native or xenograft hyaluronic acid and non-native or xenograft collagen limed or unlimed not being found at or near the wound or any other damaged tissue.

17. The method of claim 10 , wherein the substrate further comprises an effective amount of tricalcium phosphate or dense or porous hydroxyapatite in a variety of crystal sizes.

18. The method of claim 10 , wherein the substrate comprises silver nanoparticles.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT APPLICATION NO. 17/545179 TO THE CORRECT APPLICATION NO. 17545178 PREVIOUSLY RECORDED AT REEL: 060751 FRAME: 0708. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 17, 2022
From: BIOREGENTECH INC.
To: THE BIOREGENTECH INSTITUTE, INC.
Reel/Frame 061476/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2022
From: BIOREGENTECH INC.
To: THE BIOREGENTECH INSTITUTE, INC.
Reel/Frame 060751/0708 →
Continuity (5)
Continuation 15348793 · Nov 10, 2016
Continuation In Part 14937858 · Nov 10, 2015
Continuation In Part 13864226 · Apr 16, 2013
Continuation In Part 13078757 · Apr 1, 2011
Related Publication 20220257970A1 · Aug 18, 2022